Comparative Pharmacology
Head-to-head clinical analysis: MEKTOVI versus TRAMETINIB DIMETHYL SULFOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEKTOVI versus TRAMETINIB DIMETHYL SULFOXIDE.
MEKTOVI vs TRAMETINIB DIMETHYL SULFOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEKTOVI (binimetinib) is a reversible, non-competitive inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It inhibits the MAPK/ERK pathway, which is activated in tumors with BRAF mutations.
Trametinib is a reversible, selective inhibitor of MEK1 and MEK2, downstream effectors of the RAS/RAF/MEK/ERK signaling pathway, thereby inhibiting cell proliferation.
45 mg orally twice daily, approximately 12 hours apart
2 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3.7 days (range 2.5–6.3 days) in patients with advanced solid tumors. This long half-life supports once-daily dosing.
Terminal elimination half-life approximately 5.3 days (127 hours); supports once-daily dosing with steady-state achieved in ~21 days.
Primarily fecal (94% of total radioactivity) with minimal renal excretion (4% of total radioactivity). Unchanged drug accounts for approximately 27% of the dose in feces.
Primarily fecal (80%), with 20% excreted in urine; less than 0.1% recovered unchanged in urine.
Category C
Category C
MEK Inhibitor
MEK Inhibitor